Regeneron price target raised to $627 from $543 at BofA

BofA raised the firm’s price target on Regeneron (REGN) to $627 from $543 and keeps an Underperform rating on the shares. While noting that the firm’s and consensus forecasts are starting to align, the firm says “one ongoing holdback” is the company’s high relative Medicare Part B exposure, which could create an issue if a most favored nations framework, outside of company-specific deals, is pursued by the Trump administration. Good revenue and EPS growth is likely to return in 2026 and beyond after “a challenging 2025,” the analyst added.